N4 Chelating Agents for Tumor-Specific Radionuclide Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current radionuclide imaging techniques, such as PET and SPECT, face limitations in differentiating invasive lesions from edema, radiation necrosis, or gliosis, and require complex and time-consuming synthesis processes for tumor-specific imaging, particularly with 18F-FDG, which is costly and not easily accessible for simultaneous production of multiple agents.
Innovation Solution
Development of a simple chelation technique using N4 compounds and derivatives that can be chelated with various metallic isotopes, including 99mTc, for tissue-specific targeted radioimaging and radiotherapy, allowing for more efficient and specific tumor imaging and therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If complex synthesis processes are used for tumor-specific imaging (e.g., 18F-FDG), then imaging specificity is improved, but production time and cost increase
Solution Approach 1:
The patent changes the chemical parameters by using N4 compounds with specific structural features (tetraazacycloalkane rings with 4-7 atoms) that inherently provide high tumor specificity through nitrogen metabolism pathways, eliminating the need for complex multi-step synthesis processes required by traditional 18F-FDG methods
Solution Approach 2:
The invention extracts and utilizes the natural nitrogen metabolism pathways in tumor cells by designing N4 compounds that mimic endogenous nitrogen-containing molecules, allowing direct uptake and retention in tumors without requiring complex external synthesis or multiple chemical modification steps
2Adaptability or versatility
If multiple radiotracers are produced simultaneously, then imaging versatility is improved, but production complexity increases
Solution Approach 1:
The N4 compound platform serves multiple imaging functions by allowing attachment of different radionuclides (18F, 11C, 15O, 13N) to the same core molecular structure, enabling a single synthesis platform to produce multiple radiotracers for different imaging needs without requiring separate complex production lines for each tracer
3Measurement precision
If tumor-specific radiopharmaceuticals are developed, then diagnostic accuracy is improved, but manufacturing cost increases
Solution Approach 1:
The patent segments the radiopharmaceutical into a universal N4 compound core that can be synthesized once and reused, combined with different radionuclides as interchangeable components, reducing the overall manufacturing cost by eliminating redundant synthesis steps while maintaining high diagnostic accuracy through tumor-specific nitrogen metabolism targeting
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The N4 compounds enable improved tumor visualization with higher tumor-to-muscle ratios and faster synthesis times, enhancing the specificity and accessibility of tumor imaging while reducing production costs and time, thereby overcoming the limitations of existing radionuclide imaging methods.
Implementation Method 1
The present invention presents compounds and methods relating to a simple chelation technique for labeling agents using metallic isotopes
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates generally to the fields of chemistry and radionuclide imaging. More particularly, it concerns compositions, kits, and methods for imaging and therapy involving N4 compounds and derivatives.